Enveric Biosciences, Inc.
ENVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | -$0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $7 | $8 | $5 |
| G&A Expenses | $0 | $9 | $0 | $0 |
| SG&A Expenses | $6 | $9 | $11 | $20 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $16 | $20 | $25 |
| Operating Income | -$10 | -$16 | -$20 | -$26 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$1 | $0 | -$30 |
| Pre-Tax Income | -$10 | -$17 | -$20 | -$56 |
| Tax Expense | $0 | $0 | -$1 | -$7 |
| Net Income | -$10 | -$0 | -$19 | -$49 |
| % Margin | – | – | – | – |
| EPS | -228.48 | -97.08 | -87.72 | -1,244.28 |
| % Growth | -135.4% | -10.7% | 93% | – |
| EPS Diluted | -228.48 | -97.08 | -156 | -1,244.28 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$9 | -$17 | -$20 | -$56 |
| % Margin | – | – | – | – |